Connie H Miller

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4305967/publications.pdf

Version: 2024-02-01

95 papers	2,421 citations	218381 26 h-index	214527 47 g-index
96 all docs	96 docs citations	96 times ranked	1543 citing authors

#	Article	IF	Citations
1	Occurrence rates of inherited bleeding disorders other than haemophilia and von Willebrand disease among people receiving care in specialized treatment centres in the United States. Haemophilia, 2022, 28, .	1.0	3
2	Bleeding Disorders in Women and Girls: State of the Science and CDC Collaborative Programs. Journal of Women's Health, 2022, 31, 301-309.	1.5	4
3	Validation of the chromogenic Bethesda assay for factor VIII inhibitors in hemophilia a patients receiving Emicizumab. International Journal of Laboratory Hematology, 2021, 43, e84-e86.	0.7	10
4	Evaluation of antiâ€factor VIII antibody levels in patients with haemophilia A receiving immune tolerance induction therapy or bypassing agents. Haemophilia, 2021, 27, e40-e50.	1.0	1
5	Occurrence rates of von Willebrand disease among people receiving care in specialized treatment centres in the United States. Haemophilia, 2021, 27, 445-453.	1.0	13
6	The chromogenic Bethesda assay and the Nijmegenâ€Bethesda assay for factor VIII inhibitors in hemophilia A patients: Are they equivalent?. Journal of Thrombosis and Haemostasis, 2021, 19, 1835-1837.	1.9	3
7	Monitoring of von Willebrand factor inhibitors in patients with type 3 von Willebrand disease using a quantitative assay. Haemophilia, 2021, 27, 823-829.	1.0	2
8	Women and girls with haemophilia receiving care at specialized haemophilia treatment centres in the United States. Haemophilia, 2021, 27, 1037-1044.	1.0	14
9	Genetic causes of haemophilia in women and girls. Haemophilia, 2021, 27, e164-e179.	1.0	28
10	The Clinical Genetics of Hemophilia B (Factor IX Deficiency). The Application of Clinical Genetics, 2021, Volume 14, 445-454.	1.4	7
11	Evaluation of preâ€analytic heat treatment protocol used in the CDC Nijmegenâ€Bethesda assay for heat inactivation of extended halfâ€life haemophilia treatment products. Haemophilia, 2020, 26, e28-e30.	1.0	6
12	Occurrence rates of haemophilia among males in the United States based on surveillance conducted in specialized haemophilia treatment centres. Haemophilia, 2020, 26, 487-493.	1.0	41
13	Evaluation of CDCâ€™s Hemophilia Surveillance Program â€" Universal Data Collection (1998â€“2011) and Community Counts (2011â€“2019), United States. MMWR Surveillance Summaries, 2020, 69, 1-18.	18.6	26
14	Reagent substitution in the chromogenic Bethesda assay for factor <scp>VIII</scp> inhibitors. Haemophilia, 2019, 25, e342-e344.	1.0	2
15	Mathematical model of thrombin generation and bleeding phenotype in Amish carriers of Factor IX:C deficiency vs. controls. Thrombosis Research, 2019, 182, 43-50.	0.8	3
16	Coagulation Factor Testing. , 2019, , 785-788.		0
17	Specific Factor Inhibitor Testing. , 2019, , 789-792.		1
18	Platelet Aggregation Studies. , 2019, , 827-831.		0

#	Article	IF	Citations
19	Effects of pre-analytical heat treatment in factor VIII (FVIII) inhibitor assays on FVIII antibody levels. Haemophilia, 2018, 24, 487-491.	1.0	22
20	Reagent substitutions in the Centers for Disease Control and Prevention Nijmegenâ€Bethesda assay for factor <scp>VIII</scp> inhibitors. Haemophilia, 2018, 24, e116-e119.	1.0	4
21	Laboratory testing for factor <scp>VIII</scp> and <scp>IX</scp> inhibitors in haemophilia: A review. Haemophilia, 2018, 24, 186-197.	1.0	45
22	Distinguishing lupus anticoagulants from factor VIII inhibitors in haemophilic and nonâ€haemophilic patients. Haemophilia, 2018, 24, 807-814.	1.0	10
23	Limit of detection and threshold for positivity of the Centers for Disease Control and Prevention assay for factor VIII inhibitors. Journal of Thrombosis and Haemostasis, 2017, 15, 1971-1976.	1.9	16
24	Survey of the antiâ€“factor IX immunoglobulin profiles in patients with hemophilia B using a fluorescenceâ€based immunoassay. Journal of Thrombosis and Haemostasis, 2016, 14, 1931-1940.	1.9	10
25	Game, set, match for factor VIII mismatch?. Blood, 2015, 126, 829-830.	0.6	8
26	Characteristics of hemophilia patients with factor <scp>VIII</scp> inhibitors detected by prospective screening. American Journal of Hematology, 2015, 90, 871-876.	2.0	11
27	Cluster of inhibitors among adult inpatients with haemophilia in a single institution. Haemophilia, 2015, 21, e325-e328.	1.0	0
28	Improving the performance of factor VIII inhibitor tests in hemophilia A. Thrombosis Research, 2015, 136, 1047-1048.	0.8	6
29	Impact of inhibitors on hemophilia a mortality in the <scp>U</scp>nited <scp>S</scp>tates. American Journal of Hematology, 2015, 90, 400-405.	2.0	127
30	Evaluation of von Willebrand factor phenotypes and genotypes in Hemophilia A patients with and without identified F8 mutations. Journal of Thrombosis and Haemostasis, 2015, 13, 1036-1042.	1.9	14
31	Characterization of the antiâ€factorÂVIII immunoglobulin profile in patients with hemophiliaÂA by use of a fluorescenceâ€based immunoassay. Journal of Thrombosis and Haemostasis, 2015, 13, 47-53.	1.9	32
32	A Public Health Approach to the Prevention of Inhibitors in Hemophilia. American Journal of Preventive Medicine, 2014, 47, 669-673.	1.6	10
33	Laboratory testing for factor inhibitors. Haemophilia, 2014, 20, 94-98.	1.0	27
34	Females with FVIII and FIX deficiency have reduced joint range of motion. American Journal of Hematology, 2014, 89, 831-836.	2.0	43
35	Gender, race and diet affect platelet function tests in normal subjects, contributing to a high rate of abnormal results. British Journal of Haematology, 2014, 165, 842-853.	1.2	35
36	A study of prospective surveillance for inhibitors among persons with haemophilia in the United States. Haemophilia, 2014, 20, 230-237.	1.0	37

#	Article	IF	Citations
37	Mutation analysis of a cohort of US patients with hemophilia B. American Journal of Hematology, 2014, 89, 375-379.	2.0	22
38	Antiplatelet Therapy Monitoring. , 2013, , 855-859.		0
39	Platelet Aggregation Studies. , 2013, , 845-848.		0
40	The CDC Hemophilia A Mutation Project (CHAMP) Mutation List: A New Online Resource. Human Mutation, 2013, 34, E2382-E2392.	1.1	52
41	Laboratory Diagnosis of Platelet Function Defects. , 2013, , 849-854.		1
42	Comparison of clotâ€based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study. Journal of Thrombosis and Haemostasis, 2013, 11, 1300-1309.	1.9	56
43	Laboratory Assessment of Treatment of von Willebrand Disease. , 2013, , 835-836.		0
44	The <scp>CDC</scp> Hemophilia B mutation project mutation list: a new online resource. Molecular Genetics & Genomic Medicine, 2013, 1, 238-245.	0.6	49
45	Platelet Function Analyzer. , 2013, , 843-844.		0
46	Mixing Studies. , 2013, , 809-810.		0
47	Specific Factor Inhibitor Testing. , 2013, , 815-818.		0
48	Laboratory Diagnosis of Inherited von Willebrand Disease. , 2013, , 825-831.		0
49	Laboratory Diagnosis of Acquired von Willebrand Syndrome. , 2013, , 833-834.		0
50	Coagulation Factor Testing. , 2013, , 811-814.		0
51	Utility of multiplex ligationâ€dependent probe amplification (MLPA) for hemophilia mutation screening. Journal of Thrombosis and Haemostasis, 2012, 10, 1951-1954.	1.9	12
52	F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood, 2012, 119, 2922-2934.	0.6	305
53	F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity. Haemophilia, 2012, 18, 375-382.	1.0	109
54	Validation of Nijmegenâ€“Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance. Journal of Thrombosis and Haemostasis, 2012, 10, 1055-1061.	1.9	92

#	Article	IF	Citations
55	The spectrum of haemostatic characteristics of women with unexplained menorrhagia. Haemophilia, 2011, 17, e223-9.	1.0	41
56	Evaluation of a screening tool for bleeding disorders in a US multisite cohort of women with menorrhagia. American Journal of Obstetrics and Gynecology, 2011, 204, 209.e1-209.e7.	0.7	46
57	In nonâ€severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a caseâ€“control study. Journal of Thrombosis and Haemostasis, 2010, 8, 2224-2231.	1.9	60
58	Complications Associated with Carrier Status Among People with Blood Disorders. American Journal of Preventive Medicine, 2010, 38, S456-S458.	1.6	5
59	Global Tests of Primary Hemostasis. , 2009, , 615-616.		0
60	Laboratory Diagnosis of Inherited von Willebrand Disease. , 2009, , 649-652.		0
61	Mixing Studies. , 2009, , 661-662.		0
62	Laboratory Diagnosis of Acquired von Willebrand Syndrome. , 2009, , 653-654.		0
63	Laboratory Diagnosis of Acquired Platelet Function Defects. , 2009, , 627-629.		1
64	Multisite management study of menorrhagia with abnormal laboratory haemostasis: a prospective crossover study of intranasal desmopressin and oral tranexamic acid. British Journal of Haematology, 2009, 145, 212-220.	1.2	117
65	Platelet Aggregation Studies. , 2009, , 617-621.		0
66	Molecular Biology of von Willebrand Disease. , 2009, , 645-647.		0
67	Laboratory Diagnosis of Genetic Platelet Function Defects. , 2009, , 623-626.		1
68	Specific Factor Inhibitor Testing. , 2009, , 663-665.		0
69	Coagulation Factor Testing. , 2009, , 657-660.		0
70	Laboratory Assessment of Treatment of von Willebrand Disease. , 2009, , 655-656.		0
71	Laboratory response to intranasal desmopressin in women with menorrhagia and platelet dysfunction. Haemophilia, 2008, 14, 571-578.	1.0	14
72	Phenotypic and genotypic differences in factor XII between African Americans and Caucasians. Journal of Thrombosis and Haemostasis, 2007, 5, 1981-1982.	1.9	2

#	Article	IF	Citations
73	Laboratory Tests for the Diagnosis of Thrombotic Disorders. Clinical Obstetrics and Gynecology, 2006, 49, 844-849.	0.6	7
74	Screening women with menorrhagia for underlying bleeding disorders: the utility of the platelet function analyser and bleeding time. Haemophilia, 2005, 11, 497-503.	1.0	48
75	Elevated factor VII as a risk factor for recurrent fetal loss. Thrombosis and Haemostasis, 2005, 93, 1089-1094.	1.8	6
76	Age and the Prevalence of Bleeding Disorders in Women With Menorrhagia. Obstetrics and Gynecology, 2005, 105, 61-66.	1.2	124
77	Platelet functional defects in women with unexplained menorrhagia. Journal of Thrombosis and Haemostasis, 2003, 1, 477-484.	1.9	140
78	Measurement of von Willebrand factor activity: relative effects of ABO blood type and race. Journal of Thrombosis and Haemostasis, 2003, 1, 2191-2197.	1.9	121
79	Evaluation of two automated methods for measurement of the ristocetin cofactor activity of von Willebrand factor. Thrombosis and Haemostasis, 2002, 88, 56-9.	1.8	5
80	Population differences in von Willebrand factor levels affect the diagnosis of von Willebrand disease in African-American women. American Journal of Hematology, 2001, 67, 125-129.	2.0	83
81	Diagnosis of von Willebrand disease type 2N: A simplified method for measurement of factor VIII binding to von Willebrand factor. , 1998, 58, 311-318.		17
82	Alteration in age-specific risks for chromosomal trisomy by maternal serum alpha-fetoprotein and human chorionic gonadotropin screening. Prenatal Diagnosis, 1991, 11, 153-158.	1.1	13
83	Postdelivery Head Bleeding in Hemophilic Neonates. American Journal of Diseases of Children, 1989, 143, 1107.	0.5	29
84	IgG subclass identification of inhibitors to factor IX in haemophilia B patients. British Journal of Haematology, 1988, 68, 451-454.	1.2	16
85	Confirmation of autosomal dominant transmission of the DiGeorge malformation complex. Journal of Pediatrics, 1988, 113, 506-508.	0.9	25
86	Reproductive choices in hemophilic men and carriers. American Journal of Medical Genetics Part A, 1987, 26, 591-598.	2.4	23
87	Concurrence of von Willebrand's disease and hemophilia A: Implications for carrier detection and prevalence. American Journal of Medical Genetics Part A, 1986, 24, 83-94.	2.4	13
88	More about Acyclovir and Aplastic Anemia. New England Journal of Medicine, 1986, 314, 584-584.	13.9	3
89	Characterization of an occult inhibitor to factor IX in a haemophilia B patient. British Journal of Haematology, 1985, 61, 329-338.	1.2	7
90	Genetic counselling in haemophilia by discriminant analysis 1975-1980. Journal of Medical Genetics, 1982, 19, 26-34.	1.5	14

#	Article	IF	Citations
91	Factor VIII-related antigen pre-peak on crossed immunoelectrophoresis: A non-random phenomenon. Thrombosis Research, 1982, 25, 101-107.	0.8	4
92	Genetic analysis of von Willebrand's disease in two large pedigrees: A multivariate approach. American Journal of Medical Genetics Part A, 1980, 6, 279-293.	2.4	29
93	Hemophilic arthropathy: Effect of home care on treatment patterns and joint disease. Journal of Pediatrics, 1980, 97, 378-382.	0.9	15
94	Probabilistic classification of hemophilia A carriers by discriminant analysis. Thrombosis Research, 1976, 8, 683-695.	0.8	49
95	The phenotypic range of hemophilia A carriers. American Journal of Human Genetics, 1976, 28, 482-8.	2.6	20